

Roumen V Milev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/901616/publications.pdf>

Version: 2024-02-01

185
papers

10,542
citations

61984

43
h-index

36028

97
g-index

208
all docs

208
docs citations

208
times ranked

10818
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebello-cerebral Functional Connectivity Networks in Major Depressive Disorder: a CAN-BIND-1 Study Report. <i>Cerebellum</i> , 2023, 22, 26-36.	2.5	0
2	Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2023, 8, 162-170.	1.5	0
3	Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia: an international multicenter study. <i>CNS Spectrums</i> , 2022, 27, 716-723.	1.2	3
4	Baseline Functional Connectivity in Resting State Networks Associated with Depression and Remission Status after 16 Weeks of Pharmacotherapy: A CAN-BIND Report. <i>Cerebral Cortex</i> , 2022, 32, 1223-1243.	2.9	6
5	Results of the COVID-19 mental health international for the general population (COMET-G) study. <i>European Neuropsychopharmacology</i> , 2022, 54, 21-40.	0.7	84
6	What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines. <i>Journal of Affective Disorders</i> , 2022, 298, 565-576.	4.1	8
7	“One Degree of Separation”: A Mixed-Methods Evaluation of Canadian Mental Health Care User and Provider Experiences With Remote Care During COVID-19. <i>Canadian Journal of Psychiatry</i> , 2022, , 070674372110706.	1.9	6
8	Baseline anxiety, and early anxiety/depression improvement in anxious depression predicts treatment outcomes with escitalopram: A CAN-BIND-1 study report. <i>Journal of Affective Disorders</i> , 2022, 300, 50-58.	4.1	3
9	Microbial Ecosystem Therapeutic-2 Intervention in People With Major Depressive Disorder and Generalized Anxiety Disorder: Phase 1, Open-Label Study. <i>Interactive Journal of Medical Research</i> , 2022, 11, e32234.	1.4	4
10	The Effects of Ketamine on Cognition in Unipolar and Bipolar Depression. <i>Journal of Clinical Psychiatry</i> , 2022, 83, .	2.2	7
11	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders. <i>Frontiers in Psychiatry</i> , 2022, 13, 816465.	2.6	3
12	Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy. <i>Brain and Behavior</i> , 2022, 12, e2555.	2.2	3
13	Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report. <i>Psychiatry Research</i> , 2022, 312, 114557.	3.3	1
14	The impact of non-infection pandemic stress on depression and anxiety severity: Investigating mediation by intrusive and deliberate rumination. <i>Journal of Affective Disorders</i> , 2022, 310, 291-295.	4.1	5
15	Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BIND-1 study report. <i>Journal of Psychopharmacology</i> , 2022, 36, 604-613.	4.0	1
16	Rhythmicity of sleep and clinical outcomes in major depressive disorder: A CAN-BIND-1 report. <i>Journal of Affective Disorders Reports</i> , 2022, 9, 100370.	1.7	0
17	Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI in a multi-site sample: A CAN-BIND-1 report. <i>NeuroImage: Clinical</i> , 2022, 35, 103120.	2.7	8
18	The effect of different degrees of lockdown and self-identified gender on anxiety, depression and suicidality during the COVID-19 pandemic: Data from the international COMET-G study.. <i>Psychiatry Research</i> , 2022, 315, 114702.	3.3	17

#	ARTICLE	IF	CITATIONS
19	Acute and chronic stress predict anti-depressant treatment outcome and naturalistic course of major depression: A CAN-BIND report. <i>Journal of Affective Disorders</i> , 2022, 313, 8-14.	4.1	0
20	Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110194.	4.8	11
21	Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study. <i>CNS Spectrums</i> , 2021, 26, 290-298.	1.2	5
22	The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommendations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 113-125.	1.2	54
23	Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. <i>Translational Psychiatry</i> , 2021, 11, 127.	4.8	22
24	Multisite Comparison of MRI Defacing Software Across Multiple Cohorts. <i>Frontiers in Psychiatry</i> , 2021, 12, 617997.	2.6	32
25	The Efficacy, Safety, and Tolerability of Probiotics on Depression: Clinical Results From an Open-Label Pilot Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 618279.	2.6	58
26	Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. <i>CNS Drugs</i> , 2021, 35, 291-304.	5.9	4
27	Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report. <i>Pharmacopsychiatry</i> , 2021, 54, 225-231.	3.3	1
28	Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report. <i>CNS Drugs</i> , 2021, 35, 439-450.	5.9	4
29	Interactions between neuroticism and stressful life events predict response to pharmacotherapy for major depression: A CAN-BIND 1 report. <i>Personality and Mental Health</i> , 2021, 15, 273-282.	1.2	1
30	White matter microstructure in youth at risk for serious mental illness: A comparative analysis. <i>Psychiatry Research - Neuroimaging</i> , 2021, 312, 111289.	1.8	4
31	Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1. <i>PLoS ONE</i> , 2021, 16, e0253023.	2.5	4
32	Combining Ketamine and Internet-Based Cognitive Behavioral Therapy for the Treatment of Posttraumatic Stress Disorder: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2021, 10, e30334.	1.0	4
33	Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report. <i>Communications Biology</i> , 2021, 4, 903.	4.4	16
34	Why do medications with little or no efficacy continue to be prescribed in the management of patients with bipolar disorder?. <i>Bipolar Disorders</i> , 2021, 23, 541-543.	1.9	2
35	Exploring brain connectivity changes in major depressive disorder using functional-structural data fusion: A CAN-BIND study. <i>Human Brain Mapping</i> , 2021, 42, 4940-4957.	3.6	8
36	Clinical effectiveness of non-TMS neurostimulation in depression: Clinical trials from 2010 to 2020. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 110, 110287.	4.8	6

#	ARTICLE	IF	CITATIONS
37	Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response. <i>Translational Psychiatry</i> , 2021, 11, 439.	4.8	3
38	Using Electronically Delivered Therapy and Brain Imaging to Understand Obsessive-Compulsive Disorder Pathophysiology: Protocol for a Pilot Study. <i>JMIR Research Protocols</i> , 2021, 10, e30726.	1.0	2
39	Association between the expression of lncRNA <i>BASP-AS1</i> and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report. <i>Translational Psychiatry</i> , 2021, 11, 469.	4.8	1
40	The Safety and Efficacy of Microbial Ecosystem Therapeutic-2 in People With Major Depression: Protocol for a Phase 2, Double-Blind, Placebo-Controlled Study. <i>JMIR Research Protocols</i> , 2021, 10, e31439.	1.0	5
41	Cortisol reactivity to stress predicts behavioral responsivity to reward moderation by sex, depression, and anhedonia. <i>Journal of Affective Disorders</i> , 2021, 293, 1-8.	4.1	12
42	Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report. <i>Psychoneuroendocrinology</i> , 2021, 132, 105348.	2.7	8
43	Association between discrepancy in objective and subjective cognitive abilities and treatment response in patients with major depressive disorder: A CAN-BIND-1 study report. <i>Journal of Affective Disorders</i> , 2021, 295, 1095-1101.	4.1	7
44	Repetitive Transcranial Magnetic Stimulation For The Treatment of Chronic Tinnitus: A Preliminary Study of The Influence of Traumatic Brain Injury on Treatment Response. <i>International Tinnitus Journal</i> , 2021, 25, 51-58.	0.2	3
45	Double-blind, randomized, placebo-controlled crossover trial of alpha-lipoic acid for the treatment of fibromyalgia pain: the IMPALA trial. <i>Pain</i> , 2021, 162, 561-568.	4.2	10
46	Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report. <i>NeuroImage: Clinical</i> , 2021, 32, 102864.	2.7	13
47	Machine learning in the prediction of depression treatment outcomes: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2021, 51, 2742-2751.	4.5	38
48	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. <i>Bipolar Disorders</i> , 2021, 23, 767-788.	1.9	32
49	A phase 2, double-blind, placebo-controlled study of the safety and efficacy of microbial ecosystem Therapeutic-2 (MET-2) in patients with major depression: Protocol and preliminary results. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119742.	0.6	0
50	Cognition and Its Association with Psychosocial and Occupational Functioning during Treatment with Escitalopram in Patients with Major Depressive Disorder: A CAN-BIND-1 Report: La Cognition Et Son Association Avec Le Fonctionnement Psychosocial Et Professionnel Durant Le Traitement Par Escitalopram Chez Des Patients Souffrant De Trouble Dépressif Majeur: Une Étude Can-Bind-1. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 798-806.	1.9	0
51	Magnetic Resonance Imaging Sequence Identification Using a Metadata Learning Approach. <i>Frontiers in Neuroinformatics</i> , 2021, 15, 622951.	2.5	2
52	The Effects of Probiotics on Symptoms of Depression: Protocol for a Double-Blind Randomized Placebo-Controlled Trial. <i>Neuropsychobiology</i> , 2020, 79, 108-116.	1.9	28
53	Childhood maltreatment and cognitive functioning in patients with major depressive disorder: a CAN-BIND-1 report. <i>Psychological Medicine</i> , 2020, 50, 2536-2547.	4.5	17
54	Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report. <i>Neuropsychopharmacology</i> , 2020, 45, 283-291.	5.4	37

#	ARTICLE	IF	CITATIONS
55	Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression. <i>JAMA Network Open</i> , 2020, 3, e1918377.	5.9	49
56	International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 921-932.	3.2	22
57	Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 88-95.	2.1	12
58	Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study. <i>Journal of Affective Disorders</i> , 2020, 264, 414-424.	4.1	6
59	Reverse translation of major depressive disorder symptoms: A framework for the behavioural phenotyping of putative biomarkers. <i>Journal of Affective Disorders</i> , 2020, 263, 353-366.	4.1	4
60	Reliability of a functional magnetic resonance imaging task of emotional conflict in healthy participants. <i>Human Brain Mapping</i> , 2020, 41, 1400-1415.	3.6	7
61	Pre-Treatment Resting-State Functional Connectivity Related to Anhedonia and Anxiety are Associated With Antidepressant Response to Escitalopram and Adjunct Aripiprazole. <i>Biological Psychiatry</i> , 2020, 87, S431.	1.3	1
62	Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. <i>Neuropsychopharmacology</i> , 2020, 45, 1390-1397.	5.4	23
63	A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol. <i>BMC Psychiatry</i> , 2020, 20, 268.	2.6	16
64	Effect of fecal microbiota transplant on symptoms of psychiatric disorders: a systematic review. <i>BMC Psychiatry</i> , 2020, 20, 299.	2.6	120
65	An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report. <i>NeuroImage: Clinical</i> , 2020, 25, 102178.	2.7	10
66	Three insights on psychoneuroimmunology of mood disorders to be taken from the COVID-19 pandemic. <i>Brain, Behavior, & Immunity - Health</i> , 2020, 5, 100076.	2.5	18
67	Neurostimulation in Anxiety Disorders, Post-traumatic Stress Disorder, and Obsessive-Compulsive Disorder. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1191, 331-346.	1.6	28
68	Childhood maltreatment and the clinical characteristics of major depressive disorder in adolescence and adulthood.. <i>Journal of Abnormal Psychology</i> , 2020, 129, 469-479.	1.9	28
69	The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression and/or Generalized Anxiety Disorder: Protocol for a Phase 1, Open-Label Study. <i>JMIR Research Protocols</i> , 2020, 9, e17223.	1.0	11
70	Using the Online Psychotherapy Tool to Address Mental Health Problems in the Context of the COVID-19 Pandemic: Protocol for an Electronically Delivered Cognitive Behavioral Therapy Program. <i>JMIR Research Protocols</i> , 2020, 9, e24913.	1.0	23
71	Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	9
72	THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial. <i>Innovations in Clinical Neuroscience</i> , 2020, 17, 30-40.	0.1	6

#	ARTICLE	IF	CITATIONS
73	Reduced accuracy accompanied by reduced neural activity during the performance of an emotional conflict task by unmedicated patients with major depression: A CAN-BIND fMRI study. <i>Journal of Affective Disorders</i> , 2019, 257, 765-773.	4.1	20
74	Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. <i>Translational Psychiatry</i> , 2019, 9, 254.	4.8	33
75	F113. Hippocampal Subfield-Specific Sex Differences in Patients With Major Depressive Disorder. <i>Biological Psychiatry</i> , 2019, 85, S257.	1.3	0
76	White Matter Indices of Medication Response in Major Depression: A Diffusion Tensor Imaging Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2019, 4, 913-924.	1.5	21
77	Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 681-697.	2.1	28
78	Testing a deep convolutional neural network for automated hippocampus segmentation in a longitudinal sample of healthy participants. <i>NeuroImage</i> , 2019, 197, 589-597.	4.2	24
79	F107. Cortical Thickness Features Differentiate 16-Week Antidepressant Response Profiles in Major Depressive Disorder. <i>Biological Psychiatry</i> , 2019, 85, S254.	1.3	0
80	S124. Impact of CYP2C19 and CYP2D6 Genotypes on Clinical Outcomes and Side Effects in Patients Receiving Escitalopram and Aripiprazole for Major Depression: Results From the Can-Bind Cohort. <i>Biological Psychiatry</i> , 2019, 85, S344-S345.	1.3	0
81	Insulin Resistance as a Shared Pathogenic Mechanism Between Depression and Type 2 Diabetes. <i>Frontiers in Psychiatry</i> , 2019, 10, 57.	2.6	93
82	M31 IMPACT OF CYP2C19 AND CYP2D6 GENE VARIANTS ON PLASMA LEVELS AND TREATMENT RESPONSE IN PATIENTS RECEIVING ESCITALOPRAM AND ARIPIPRAZOLE FOR MAJOR DEPRESSION: RESULTS FROM THE CAN-BIND-1 COHORT. <i>European Neuropsychopharmacology</i> , 2019, 29, S183.	0.7	0
83	Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. <i>Psychological Medicine</i> , 2019, 49, 1629-1638.	4.5	22
84	The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, 223-236.	2.4	37
85	Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	61
86	Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	16
87	Functional competence in major depressive disorder: Objective performance and subjective perceptions. <i>Journal of Affective Disorders</i> , 2018, 234, 1-7.	4.1	9
88	Canadian Network for Mood and Anxiety Treatments (<sc>CANMAT</sc>) and International Society for Bipolar Disorders (<sc>ISBD</sc>) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disorders</i> , 2018, 20, 97-170.	1.9	1,079
89	Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 128-144.	2.1	68
90	Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials. <i>Journal of Affective Disorders</i> , 2018, 226, 294-300.	4.1	7

#	ARTICLE	IF	CITATIONS
91	The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study. <i>Journal of Affective Disorders</i> , 2018, 227, 542-549.	4.1	59
92	The experience and impact of stigma in Saudi people with a mood disorder. <i>Annals of General Psychiatry</i> , 2018, 17, 51.	2.7	21
93	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments. <i>Focus (American Psychiatric Publishing)</i> , 2018, 16, 85-94.	0.8	12
94	The effects of probiotics on depressive symptoms in humans: a systematic review. <i>Annals of General Psychiatry</i> , 2017, 16, 14.	2.7	284
95	A National Survey on Nursing in Canadian ECT Departments. <i>Archives of Psychiatric Nursing</i> , 2017, 31, 302-305.	1.4	1
96	Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression Guidelines. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 77-78.	1.9	0
97	Response to Letter Regarding CANMAT Recommendations for the Pharmacological Treatment of Late-life Depression. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 353-354.	1.9	0
98	Repetitive transcranial magnetic stimulation of the right dorsal lateral prefrontal cortex in the treatment of generalized anxiety disorder: A randomized, double-blind sham controlled clinical trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 78, 61-65.	4.8	57
99	MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. <i>Nature Communications</i> , 2017, 8, 15497.	12.8	144
100	The Default Mode Network in Healthy Individuals: A Systematic Review and Meta-Analysis. <i>Brain Connectivity</i> , 2017, 7, 25-33.	1.7	240
101	Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression. <i>Scientific Reports</i> , 2017, 7, 7473.	3.3	28
102	Olfactory Functioning and Depression: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2017, 8, 190.	2.6	59
103	Innovations in the Management of Musculoskeletal Pain With Alpha-Lipoic Acid (IMPALA Trial): Study protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of Alpha-Lipoic Acid for the Treatment of Fibromyalgia Pain. <i>JMIR Research Protocols</i> , 2017, 6, e41.	1.0	5
104	Pain Improvement With Novel Combination Analgesic Regimens (PAIN-CARE): Randomized Controlled Trial Protocol. <i>JMIR Research Protocols</i> , 2017, 6, e111.	1.0	5
105	Combination Analgesic Development for Enhanced Clinical Efficacy (CADENCE Trial): Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of an Alpha-Lipoic Acid and Pregabalin Combination for the Treatment of Fibromyalgia Pain. <i>JMIR Research Protocols</i> , 2017, 6, e154.	1.0	2
106	The role of electroconvulsive therapy in the treatment of bipolar disorder. , 2017, , .		0
107	Functional Recovery in Major Depressive Disorder. primary care companion for CNS disorders, <i>The</i> , 2016, 18, .	0.6	51
108	Transcranial Magnetic Stimulation of the Supplementary Motor Area in the Treatment of Obsessive-Compulsive Disorder: A Multi-Site Study. <i>International Journal of Molecular Sciences</i> , 2016, 17, 420.	4.1	64

#	ARTICLE	IF	CITATIONS
109	Discrimination in the workplace, reported by people with major depressive disorder: a cross-sectional study in 35 countries. <i>BMJ Open</i> , 2016, 6, e009961.	1.9	52
110	The manic phase of Bipolar disorder significantly impairs theory of mind decoding. <i>Psychiatry Research</i> , 2016, 239, 275-280.	3.3	14
111	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 506-509.	1.9	58
112	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 588-603.	1.9	165
113	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 510-523.	1.9	209
114	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 540-560.	1.9	746
115	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 524-539.	1.9	340
116	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 561-575.	1.9	415
117	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 576-587.	1.9	227
118	Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial. <i>Pain</i> , 2016, 157, 1532-1540.	4.2	74
119	Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. <i>BMC Psychiatry</i> , 2016, 16, 105.	2.6	114
120	Harnessing the potential of community-based participatory research approaches in bipolar disorder. <i>International Journal of Bipolar Disorders</i> , 2016, 4, 4.	2.2	33
121	Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. <i>Molecular Psychiatry</i> , 2016, 21, 1050-1056.	7.9	42
122	The Depression Inventory Development Workgroup: A Collaborative, Empirically Driven Initiative to Develop a New Assessment Tool for Major Depressive Disorder. <i>Innovations in Clinical Neuroscience</i> , 2016, 13, 20-31.	0.1	11
123	Delivery of Electroconvulsive Therapy in Canada. <i>Journal of ECT</i> , 2015, 31, 119-124.	0.6	16
124	Comparison of stigmatizing experiences between Canadian and Korean patients with depression and bipolar disorders. <i>Asia-Pacific Psychiatry</i> , 2015, 7, 383-390.	2.2	3
125	Response of Depression to Botulinum Toxin Treatment: Agitation as a Predictor. <i>Frontiers in Psychiatry</i> , 2015, 6, 55.	2.6	1
126	Maintenance Repetitive Transcranial Magnetic Stimulation (RTMS) in Relapse Prevention of Depression. <i>European Psychiatry</i> , 2015, 30, 836.	0.2	1

#	ARTICLE	IF	CITATIONS
127	Cross-national variations in reported discrimination among people treated for major depression worldwide: The ASPEN/INDIGO international study. <i>British Journal of Psychiatry</i> , 2015, 207, 507-514.	2.8	47
128	Towards a Better Future for Canadians with Bipolar Disorder: Principles and Implementation of a Community-Based Participatory Research Model. <i>Engaged Scholar Journal Community-Engaged Research Teaching and Learning</i> , 2015, 1, 132-147.	0.1	7
129	Sleep architecture and cognitive changes in olanzapine-treated patients with depression: A double blind randomized placebo controlled trial. <i>BMC Psychiatry</i> , 2014, 14, 202.	2.6	33
130	Utility of the Berlin questionnaire for predicting obstructive sleep apnea in individuals with treatment-resistant depression. <i>Sleep and Breathing</i> , 2013, 17, 1221-1227.	1.7	15
131	Global pattern of experienced and anticipated discrimination reported by people with major depressive disorder: a cross-sectional survey. <i>Lancet, The</i> , 2013, 381, 55-62.	13.7	331
132	Identification of primary polydipsia in a severe and persistent mental illness outpatient population: A prospective observational study. <i>Psychiatry Research</i> , 2013, 210, 679-683.	3.3	26
133	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. <i>Bipolar Disorders</i> , 2013, 15, 1-44.	1.9	740
134	The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. <i>Bipolar Disorders</i> , 2013, 15, 58-60.	1.9	14
135	Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated Bipolar Disorder Guidelines. <i>Bipolar Disorders</i> , 2013, 15, 338-339.	1.9	1
136	Delivery of Electroconvulsive Therapy in Canada. <i>Journal of ECT</i> , 2013, 29, 225-230.	0.6	11
137	Cognitive Remediation for Treatment-Resistant Depression. <i>Journal of Nervous and Mental Disease</i> , 2013, 201, 680-685.	1.0	119
138	Electroconvulsive Therapy Teaching in Canada. <i>Journal of ECT</i> , 2013, 29, 109-112.	0.6	9
139	Relationships Among Neurocognition, Symptoms, and Functioning in Treatment-Resistant Depression. <i>Archives of Clinical Neuropsychology</i> , 2013, 28, 272-281.	0.5	42
140	Sleep architecture in ziprasidone-treated bipolar depression: a pilot study. <i>Therapeutic Advances in Psychopharmacology</i> , 2013, 3, 139-149.	2.7	15
141	Effects, experiences, and impact of stigma on patients with bipolar disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 31.	2.2	20
142	A review of electroencephalographic changes in diabetes mellitus in relation to major depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 143.	2.2	19
143	Canadian Survey of Perianesthetic Care for Patients Receiving Electroconvulsive Therapy. <i>Journal of ECT</i> , 2012, 28, 219-224.	0.6	8
144	Stigma and Discrimination in People Suffering with a Mood Disorder: A Cross-Sectional Study. <i>Depression Research and Treatment</i> , 2012, 2012, 1-9.	1.3	21

#	ARTICLE	IF	CITATIONS
145	The Canadian Biomarker Integration Network in Depression (CAN-BIND): Advances in Response Prediction. <i>Current Pharmaceutical Design</i> , 2012, 18, 5976-5989.	1.9	61
146	The Canadian Survey of Standards of Electroconvulsive Therapy Practice: A Call for Accreditation. <i>Canadian Journal of Psychiatry</i> , 2012, 57, 634-642.	1.9	10
147	The neurobiology of the EEG biomarker as a predictor of treatment response in depression. <i>Neuropharmacology</i> , 2012, 63, 507-513.	4.1	148
148	Effects of Electroconvulsive Therapy and Repetitive Transcranial Magnetic Stimulation on Serum Brain-Derived Neurotrophic Factor Levels in Patients with Depression. <i>Frontiers in Psychiatry</i> , 2012, 3, 12.	2.6	60
149	Anticipated discrimination among people with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2012, 125, 77-83.	4.5	58
150	A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of High-Dose Quetiapine in Patients With Persistent Symptoms of Schizophrenia or Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 13-20.	2.2	26
151	Clinical effectiveness: The importance of psychosocial functioning outcomes. <i>Journal of Affective Disorders</i> , 2011, 132, S9-S13.	4.1	76
152	Public knowledge, beliefs and attitudes towards patients with schizophrenia: Buenos Aires. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2011, 46, 281-290.	3.1	40
153	Access to Electroconvulsive Therapy Services in Canada. <i>Journal of ECT</i> , 2011, 27, 300-309.	0.6	18
154	Frequency and Correlates of Gambling Problems in Outpatients with Major Depressive Disorder and Bipolar Disorder. <i>Canadian Journal of Psychiatry</i> , 2010, 55, 568-576.	1.9	44
155	Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression. <i>Neuropsychiatric Disease and Treatment</i> , 2010, 6, 501.	2.2	27
156	An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study. <i>International Journal of Clinical Practice</i> , 2010, 64, 1520-1529.	1.7	3
157	Psychiatric human resources planning in Canada. Position paper. Canadian Psychiatric Association. <i>Canadian Journal of Psychiatry</i> , 2010, 55, 1-20.	1.9	11
158	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.. <i>Journal of Affective Disorders</i> , 2009, 117, S44-S53.	4.1	175
159	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.. <i>Journal of Affective Disorders</i> , 2009, 117, S26-S43.	4.1	357
160	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. <i>Bipolar Disorders</i> , 2009, 11, 225-255.	1.9	545
161	Mortality over a 20-year period in patients with primary polydipsia associated with schizophrenia: A retrospective study. <i>Schizophrenia Research</i> , 2009, 107, 128-133.	2.0	51
162	A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: The PLATYPUS Study. <i>Schizophrenia Research</i> , 2009, 113, 41-48.	2.0	29

#	ARTICLE	IF	CITATIONS
163	Geographic Accessibility of ECT Services in Canada. <i>Journal of ECT</i> , 2009, 25, 149.	0.6	0
164	Repetitive Transcranial Magnetic Stimulation for Treatment of Medication-Resistant Depression in Older Adults. <i>Journal of ECT</i> , 2009, 25, 44-49.	0.6	17
165	Stigma in patients with bipolar disorders. <i>Annals of General Psychiatry</i> , 2008, 7, .	2.7	0
166	MEDS. <i>Journal of Affective Disorders</i> , 2008, 107, S27.	4.1	1
167	Multisensory Stimulation for Elderly With Dementia: A 24-Week Single-Blind Randomized Controlled Pilot Study. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2008, 23, 372-376.	1.9	50
168	rTMS added to usual treatment for older patients with depression. <i>European Psychiatry</i> , 2007, 22, S265.	0.2	0
169	Differential control of the scapulothoracic muscles in humans. <i>Journal of Physiology</i> , 2007, 580, 777-786.	2.9	34
170	Repetitive transcranial magnetic stimulation for treatment of elderly patients with depression - an open label trial. <i>Neuropsychiatric Disease and Treatment</i> , 2007, 3, 919-24.	2.2	17
171	Panic disorder. <i>Lancet, The</i> , 2006, 368, 1023-1032.	13.7	208
172	P.2.g.002 Repetitive transcranial magnetic stimulation for treatment of older patients with depression - an open label trial. <i>European Neuropsychopharmacology</i> , 2006, 16, S358.	0.7	0
173	Add-on Quetiapine for Bipolar Depression: A 12-Month Open-Label Trial. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 523-530.	1.9	19
174	Clinical Outcome and Memory Function With Maintenance Electroconvulsive Therapy. <i>Journal of ECT</i> , 2006, 22, 43-45.	0.6	15
175	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. <i>Bipolar Disorders</i> , 2006, 8, 721-739.	1.9	202
176	Add-on quetiapine for bipolar depression: twelve months open label prospective trial. <i>Annals of General Psychiatry</i> , 2006, 5, 1.	2.7	0
177	T3 augmentation of SSRI resistant depression. <i>Journal of Affective Disorders</i> , 2006, 91, 211-215.	4.1	78
178	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. <i>Bipolar Disorders</i> , 2005, 7, 5-69.	1.9	321
179	Functional modulation of shoulder girdle stability. <i>Experimental Brain Research</i> , 2005, 161, 417-422.	1.5	14
180	No Association Between the Putative Functional ZDHC8 Single Nucleotide Polymorphism rs175174 and Schizophrenia in Large European Samples. <i>Biological Psychiatry</i> , 2005, 58, 78-80.	1.3	41

#	ARTICLE	IF	CITATIONS
181	Strong evidence for association between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia in 488 parent-offspring trios from Bulgaria. <i>Biological Psychiatry</i> , 2004, 55, 971-975.	1.3	149
182	Switch to Mania upon Discontinuation of Antidepressants in Patients with Mood Disorders: A Review of the Literature. <i>Canadian Journal of Psychiatry</i> , 2003, 48, 258-264.	1.9	33
183	Risk of schizophrenia increased with increasing paternal age. <i>Evidence-Based Mental Health</i> , 2001, 4, 123-123.	4.5	0
184	Integrated Genome-Wide Methylation and Expression Analyses Reveal Functional Predictors of Response to Antidepressants. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
185	COVID-19 Pandemic: The Impact of COVID-19 on Mental Health and Life Habits in the Canadian Population. <i>Frontiers in Psychiatry</i> , 0, 13, .	2.6	4